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A bstract The lateral mobility of membrane proteins can reflect 
the extent of various protein-protein interactions. Using the fluo- 
rescence recovery after photobleaching technique, we have stud- 
ied the lateral mobility of human FcyRIIa and some FcyRIIa 
mutants expressed in either P388D1 cells, a mouse macrophage- 
like cell line, or in Chinese hamster ovary (CHO) cells [1]. After 
treatment with phorbol myristate acetate (PMA), only the 
FcyRIla molecules capable of mediating rapid endocytosis of 
intmune complexes exhibited a reduced lateral diffusion coeffi- 
cient with respect o untreated controls. Wild type FcyRIla ex- 
pressed in CHO cells, and nonfunctional FcyRIIa mutants ex- 
pressed in P388D1 cells did not show any differences upon PMA 
treatment. This finding suggests that protein kinase C activation 
e~okes additional protein-protein interactions with the cytoplas- 
mic domain of functional FcyRIIa, which reduced receptor lat- 
eral mobility. The identity of these putative interacting proteins 
and the nature of the interactions remain to be elucidated. 
1~ ey words: Fc receptor; Protein kinase C; Fluorescence 
r~ covery after photobleaching; Lateral mobility 
1 Introduction 
Human FcyRIIa (CD32) is widely expressed on hematopoi- 
e~ic cells, including macrophages, neutrophils, and platelets, 
a,ld, like other multichain immune response receptors, is acti- 
~ted after cross-linking by immune complexes or antigens [2]. 
! cyRIIa participates in the endocytic learance of soluble im- 
r~ rune complexes, phagocytosis oflarge particles, and the oxida- 
tive burst. The receptor has a modified immune receptor tyro- 
sne activation motif (ITAM), which consists of two YXXL 
t Lotifs with the tyrosines eparated by 15 amino acids, instead 
(,fthe 10-11 residues found in the consensus sequence for other 
i ~embers of the family. A functional study of a set of mutants 
i~ the cytoplasmic domain of Fc),RIIa has revealed that the 
( 'OOH-terminal YXXL motif is required for [Ca2+]~ flux and 
l'hagocytosis following stimulation, but is not required for en- 
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docytosis of immune complexes. Several mutations in the NH2- 
YXXL motif (Tyr 252 to Phe, and Leu 255 to Glu) result in a more 
severely crippled phenotype, which will endocytose only very 
extensively cross-linked immune complexes. Signal transduc- 
tion by FcyRIIa in macrophages is associated with the activa- 
tion of Src kinases, the tyrosine kinase p72 ~yk, and tyrosine 
phosphorylation f numerous cellular substrates. These results 
suggest hat various cytoplasmic molecules interact with the 
cytoplasmic domain of the receptor following its activation. 
There is evidence that protein kinase C plays a role in 
Fc),RIIa-mediated responses, because phorbol esters increase 
phagocytosis n neutrophils and macrophages [3-8]. Further- 
more, Zheleznyak and Brown have shown that the PKC activa- 
tion is a required early step for FcR mediated phagocytosis by 
human monocytes [9]. Incubation of monocytes with IgG-op- 
sonized targets increased membrane-associated PKC which 
precedes the ingestion. Phorbol myristate acetate inhibits the 
[Ca2+]~ flux due to FcyRIIa activation and also inhibits the 
tyrosine phosphorylation f Shc, an SH2 adapter protein [10]. 
These results uggest that one or more PKC isozymes interacts 
either with FcyRIIa or with other cytosolic factors in the sig- 
naling complex. 
In this work, we devised an in situ means to test the propo- 
sition that FcyRlla interacts with additional cytoplasmic or 
cytoskeletal components after phorbol esters induce phospho- 
rylation of cellular components. This test is based upon the fact 
that the lateral mobility of a given membrane protein will reflect 
the extent of its interactions with other membrane proteins as 
well as with proteins in the cytoplasm and pericellular matrix 
[11]. Using the fluorescence recovery after photobleaching 
(FRAP) technique to measure changes in receptor lateral mo- 
bility associated with receptor activation, we can therefore infer 
changes in protein protein interactions upon FcyRIIa activa- 
tion. Furthermore, by comparing the lateral mobility of wild 
type FcyRIIa and cytoplasmic domain mutants, we can largely 
confine our attention to the interactions of cytoplasmic domain 
FcyRIIa with cytosolic proteins. 
However, because FcyRs are activated by cross-linking of 
receptors induced by multivalent immune complexes or, exper- 
imentally, by cross-linking anti-FcyR antibodies, lateral mobil- 
ity measurements under normal receptor activation conditions 
are not feasible. To circumvent this difficulty, we employ PMA 
to intervene in the putative signaling pathway downstream 
from the cross-linking step. 
Fc?'Rlla and mutants with either cytoplasmic domain trun- 
cations or amino acid substitutions were transfected into 
P388D1 and Chinese hamster ovary (CHO) cells ([1], Lin and 
Unkeless, unpublished). We then compared the lateral mobility 
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of wild type FcyRI Ia in the P388D1 and CHO lines to that of 
Fc~,RIIa mutants expressed in P388D1 cells. Mutant FcTRIIa 
include A264 competent to endocytose immune complexes but 
not to phagocytose EIgG or flux [Ca2+]~ (z1264), and mutations 
(Y252F, A233, and A207) that cripple or inactivate ndocytosis 
as well as phagocytosis and [Ca2+]i flux. After PMA treatment, 
only those Fc~,RIIa molecules capable of mediating rapid endo- 
cytosis of immune complexes exhibited reduced lateral mobility 
suggesting that, indeed, PKC activation did induce additional 
protein-protein i teractions with the cytoplasmic domain of 
functional receptor. 
2. Materials and methods 
2.1. Constructs of human FcyRlla cDNAs and transfected cell lines 
Constructs of wild type human FcyRIIa and mutants and transfec- 
tion protocols for macrophages have been described in detail [1]. The 
Y252L mutation was made by oligonucleotide-directed mutagenesis 
[12]. Stable transfectants of the wild type huFcyRIIa and its mutant 
forms have been expressed in a mouse macrophage-like c ll line, 
P388D1 cells, and in CHO cells. 
All the permanently transfected cells were grown in DMEM-H me- 
dium supplemented with 5% heat-inactivated f tal calf serum (FCS), 
penicillin ( 100 U/ml), streptomycin (100/.tg/ml), and 0.2 mg/ml G-418 
(Gibco, Grand Island, NY). P388DI cells were plated on 12 x 12-mm 
coverslip in 35-mm dishes about 0.5-1 h before the microscopic studies, 
while the CHO cells were plated for 24 h before use. 
2.2. Antibody &be&for FRAP studies 
FITC-conjugated monoclonal antibody IV.3 IgG was purchased 
from Medarex (Hanover, NH). The plated cells were labeled with 30 
/zg/ml antibody in PBS(+) at room temperature for 10 rain. When 
murine C3H 10TI/2 cells were incubated with the IV.3 antibody, the 
level of staining was negligible. 
2.3. Protein kinase C activation and inhibition 
50 ng/ml of phorbol 12-myristate 13-acetate (PMA) (Sigma, St. 
Louis, MO) in PBS(+) was used for activating PKC. The PMA was 
added immediately before and remained throughout the FRAP experi- 
ment. 50 ng/ml of the non-active phorbol ester 4~-phorbol 12,13-dide- 
canoate (4ctPDD) (Sigma, St. Louis, MO) was used as a control. 100 
nM of Calphostin C (Calbiochern, CA) in PBS(+) was used for inhibit- 
ing PKC activity. The Calphostin C was added with labeling antibody 
and remained throughout the FRAP experiment. 
2.4. Fluorescence recovery after photobleaching (FRAP) 
FRAP measurements were made at room temperature employing a 
40x oil objective (n.a., 1.3) to focus the laser beam to a diameter of 
approximately 2.0 ~tm. A pulse mode recording and low monitoring 
power were employed to minimize the fading during the experiment 
[13]. The 488 nm line of a Spectra-Physics 164-07 argon ion laser 
(Mountain View, CA) was used. Spots on the cell were bleached for 20 
ms using a laser power of about 50 mW. The recovery phase was 
interrogated with beam powers of about 5/IW. A single curve was 
recorded per cell, and each coverslip was used for less than one hour 
after antibody labeling. 
2.5. Analysis of PKC-6 
P388D1 cells transfected with wt Fc},Rlla were maximally stimulated 
by ligating the receptor to a glass substrate. Proteins were covalently 
coupled to glass as described [14]. Glass petri dishes were acid washed 
with 20% H2SO 4, neutralized with 0.1 N NaOH, rinsed with water, 
dried, and derivatized with 3-aminopropyltriethoxysilane (Sigma) for 
4 min at room temperature (rt). After rinsing with phosphate-buffered 
saline (PBS), the dishes or coverslips were incubated with 0.25% glu- 
taraldehyde (Sigma) for 30 min followed by incubation with 5/~g/ml of 
F(ab')2 anti-mouse IgG (Jackson Immunoresearch) in PBS for 1 h at 
rt. The dishes were rinsed with PBS, and cells (1 x 10616 cm dish) 
suspended inmedium containing 2% FCS were allowed to adhere for 
30 rain at 37°C. Finally, mAb IV.3 Fab was added to a final concentra- 
tion of 1/zg/ml and incubated for 30 min at 37°C, 
Control cells or cells treated with PMA (100 ng/ml, 30 min at 37°C) 
were activated as described, lysed in 0.5% NP-40, and immunoprecipi- 
tated with anti-phosphotyrosine mAb 4GI0. Immunoprecipitates w re 
collected with protein A-agarose (Pierce, Rockford, IL). Lysates and 
immunoprecipitates w re subjected to SDS-PAGE, electroeluted onto 
nitrocellulose, and immunoblotted with either mAb 4G10, or with a 
specific rabbit anti-PKC6 IgG, which is directed against a peptide 
epitope (657 673) of rat PKC~ and not crossreactive with ct, ill, flII, 
y, e or e or r/isozymes (Santa Cruz Biotechnology, Santa Cruz, CA). 
Bound rabbit IgG or mouse IgG was detected using alkaline phosphat- 
ase-conjugated secondary antibody (Jackson Immunoresearch) and de- 
tected with nitro-blue tetrazolium chloride and 5-bromo-4-chloro-Y- 
indolyphosphate p-toluidine salt (Pierce) as substrate. 
3. Results and discussion 
3.1. Lateral mobility & rest&g state 
The huFcTRIIa mutants examined for lateral mobility cov- 
ered a wide range of cytoplasmic domain modifications, The 
mutants differ in their signaling capabilities. The non-func- 
tional truncation mutants A207 and A233 have cytoplasmic 
domains of two and twenty-eight amino acids. A264, which has 
a cytoplasmic domain of fifty-nine amino acids, has lost the 
ability to mediate phagocytosis of erythrocytes coated with 
IV.3 Fab (E-IV.3 Fab) and to stimulate a [Ca2+]i flux, but 
endocytoses immune complexes normally. The point mutant 
Y252L has a Tyr-to-Leu substitution at position 252, which 
results in a failure to mediate phagocytosis or [Ca2+]i flux. This 
mutant will only mediate endocytosis of extensively cross- 
linked complexes compared to wild type receptor (Lin and 
Unkeless, unpublished results). 
The wild type huFcyRI Ia is functional in P388D1 cells but 
not in CHO cells [1], and the pattern of tyrosine phosphoryla- 
tion following receptor cross-linking in P388D1 cells is compa- 
rable to that seen in the human monocytic ell line U937. The 
P388D~ cells thus appear to possess the cytoplasmic factors 
required for huFcyRI Ia mediated responses. By comparing the 
lateral mobility of FcyRIIa and its various mutants, we hoped 
to be able to monitor the interactions between these factors and 
the FcyRIIa cytoplasmic domain. 
The lateral mobility data in terms of diffusion coefficient (D) 
and mobile fraction for wild type huFc),RIIa and its mutants 
are compared in Table 1. The diffusion coefficients for all the 
constructs are at the high end of the range for membrane 
spanning proteins [15]. The implication is that there is little 
interaction between FcyRI Ia cytoplasmic domain and cytosolic 
factor(s) in the resting state. Progressive truncation of the cyto- 
plasmic domain to twenty-eight and two amino acids (A233 and 
3207) resulted in a progressive depression in D, compared to 
wt FcyRIIa expressed in either CHO or P388D1 cells. One 
possible interpretation is that the intact cytoplasmic domain 
inhibits either transmembrane or extracellular domain interac- 
tions, and thus the FcTRIIa cytoplasmic domain truncations 
result in a more highly aggregated receptor and hence lower 
mobility than the native FcyRIIa. 
3.2. Lateral mobility in PMA-treated cells 
FcyRs are activated by cross-linking of receptors induced by 
multivalent immune complexes or, experimentally, by cross- 
linking anti-FcyR antibodies. Under these circumstances lat- 
eral mobility measurements are not feasible. In order to inter- 
vene in the signal transduction pathway downstream from the 
cross-linking step, receptor lateral mobility was measured after 
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Table 1 
Lateral mobility of Fc receptors 
79 
Constructs Endocytic 50 ng/ml DC Mobile Number of 
competence a PMA (x 10 t(~ cm2/s) fraction (%) measurements 
Wiid type in P388D1 +++ - 13.9 _+ 2.1 53.6 + 4.1 56 
+ 6.4 + 0.7* 53.1 + 3.8 91 
+(+CaI-C) b 14.9 + 2.0** 70.8 + 4.8 42 
A2~i4 in P388D1 ++ - 14.4 + 2.2 51.3 _+ 5.1 40 
+ 7.2 + 1.0" 48.0 _+ 4.9 43 
Y~52L in P388D1 + - 7.1 + 0.7 71.0 + 4.0 20 
+ 7.4 + 0.8** 67.0 + 3.0 20 
A2 ~3 in P388D1 - - 9.8 + 1.0 65.8 _+ 3.5 16 
+ 10.4 _+ 1.9"* 65.6 +_ 4.6 17 
A2)7 in P388DI - - 8.5 _+ 1.1 61.8 _+ 4.4 28 
+ 8.3 _+ 1.0"* 53.9 + 4.0 23 
Wild type in CHO - - 15.6 + 1.5 78.8 +_ 1.7 25 
+ 16.7 + 1.3"* 79.9 + 1.9 25 
*S udent's t-test, P < 0.01, mean + S.E.M. 
** Not significant with reference to cells not treated with PMA. 
4 ~-+ = phagocytic competent; ++ = endocytose immune complex; + = endocytose large ~mmune complex; -, incompetent. 
bll '0 nM of Calphostin added (see section 2). 
in,'ubation with PMA. This strategy was adopted because there 
is ,,widence to suggest hat PKC participates in FcyR signaling. 
D~acylglycerol has been reported to potentiate macrophage 
F, ?'R-mediated phagocytosis [4]. The activity of protein kinase 
C was elevated after EIgG stimulation [8], and immune com- 
pl~:x endocytosis was inhibited by PKC inhibitors [1,5,9]. Fur- 
th,~rmore, preceding ingestion of IgG-opsonized targets by 
monocytes, there is increased membrane-associated PKC [9]. 
PMA also blunted the [Ca2+]i flux triggered by FcyRI Ia liga- 
tic,n, and inhibited the tyrosine phosphorylation of Shc [10]. It 
w,ts expected that the additional interactions evoked by PKC 
activation would be reflected in reductions of huFcyRI Ia  lat- 
eral mobility, because the lateral mobility of membrane pro- 
te~ns can be altered by binding to other protein(s). For example, 
o~ the external surface of the plasma membrane, the diffusion 
c(,efficient of Thy-1 is reduced by about 70% by binding to 
al~ti-Thy-1 IgG [13]. 
The effect of PMA treatment on mobility of wild type 
F~7/RIIa and its mutants is given in absolute terms in Table 1 
a~d relative terms in Table 2. It is striking that the lateral 
d;Tusion of FcyRI Ia was reduced by 50% following PMA 
tr~:atment only in those cell lines capable of endocytosis of 
in mune complexes (wt FcT'RIIa and the A264 truncation trans- 
fer:ted into P388D1 cells). The A264 mutation does not support 
either [Ca2+]i flux or phagocytosis [1]. This diffusion coefficient 
re' :luction, mediated by PMA treatment, can be blocked by 
acding Calphostin C, a PKC inhibitor. The inactive phorbol 
e,~ :er, 4~PDD, had no effect, ruling out a nonspecific effect of 
li~,id binding. The diffusion coefficient of Y252L, a severely 
ct ppled FcyRI Ia mutant that endocytoses immune complexes 
o~ly at high cross-linker concentration, was not affected by 
PMA, nor were the nonfunctional deletion mutants A233 and 
A_:07. Finally, the diffusion coefficient of wt FcyRI Ia  trans- 
fe,:ted into CHO cells, in which the receptor does not support 
pl tagocytosis, immune complex endocytosis, or [Ca2+]i flux was 
unaffected by PMA. 
These observations provide the first in situ evidence suggest- 
ing the PKC activation evokes interaction(s) between the 
Fc~'RIIa cytoplasmic domain and cytoplasmic protein(s). The 
PKC-8 isoform is highly expressed in myeloid cells [16] and is 
tyrosine-phosphorylated upon activation with PMA [17]. In- 
deed, following incubation of P388D1, cells with PMA, tyro- 
sine phosphorylation of an 74,000 Mr protein (the size of PKC- 
6) was induced (Fig. 1). Furthermore, immunoblotting of an 
anti-phosphotyrosine immunoprecipitate with an anti-PKC-8 
antibody revealed the presence of tyrosine phosphorylated 
PKC-8 in both P388D1, cells stimulated by FcyRI Ia ligation, 
and treated with PMA (Fig. 1). In vitro, Src is reported to 
phosphorylate PKC-8, but acts only on the activated form of 
the enzyme, following PMA activation [18], And, PKC-8 is 
reported to associate with FceRIfl chain and to phosphorylate 
the y-chain on threonine in vivo [19]. It is possible that other 
PKC isoforms are also activated by FcyRI Ia cross-linking. 
Thus it is likely that activation of FcyRI Ia activates one or 
more PKC isoforms, which would in turn prime receptors for 
endocytosis of immune complexes, even on those receptors that 
Table 2 
Effects of PKC activation and inhibition on Fc-R lateral mobility 
Receptor Agent added a Relative mobility b
(D,ge,1,/Dcon~,ol) 
WT 1.0 
WT PMA 0.46 _+ 0.09 
WT 4~PDD 0.97 _+ 0.08 
WT PMA + Calphostin 1.07 + 0.20 
WT (in CHO) PMA 1.07 + 0.13 
Y252L PMA 1.04 _+ 0.14 
A264 PMA 0.50 + 0.10 
A233 PMA 1.06 + 0.22 
A207 PMA 0.98 + 0.16 
~See section 2 for details. 
bFormula for standard error: c= a/b, (Ac) 2 = (Aa/b) 2 + (aAb/b 2)2. 
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PMA + + + + 
Crossllnking - -  + - -  + - -  + - -  + 
II ! I I  
vv  
Cell lysates ip: anti-PY 
Blot: anti-PY anti-PKC~ 
Fig. 1. Tyrosine phosphorylation f PKC-~. P388D1 cells transfected 
with FcyRIIa were plated on goat anti-mouse IgG F(ab')2 coated glass 
dishes in either presence or absence of 100 ng/ml PMA, and the recep- 
tors were then activated by adding IV.3 Fab (1/.tg/ml) for 30 min at 
37°C. Cells were then scraped and lysed in 0.5% NP-40 lysis buffer. The 
cell lysates were blotted with mAb 4G10, and the 4G 10 immunoprecip- 
itates were probed with a polyclonal anti-PKC-d IgG. 
may not have bound immune complexes yet. This 'priming' 
may involve additional interactions with cytoplasmic factors 
that serve to reduce the diffusion coefficient. The identity of the 
putative interacting proteins and the nature of the interactions 
remain to be elucidated. 
The ability to detect membrane protein-cytoplasmic fa tor 
interactions by reductions in the lateral mobility of the mem- 
brane protein may offer a general method for studying interac- 
tions of this type, in situ. A generic ytoplasmic domain inter- 
action detector could be envisioned with the capability of de- 
tecting changes in the lateral mobility of the detector protein. 
Such a detector molecule could be constructed as a chimera 
produced by fusing the ectodomain and transmembrane do- 
main from a protein with high diffusion coefficient with the 
cytoplasmic domain of a protein under investigation. This de- 
tector molecule could be expressed in a cell type which does not 
normally express the wild type ectodomain of the reporter mol- 
ecule. Detector proteins exhibiting a large D would allow a 
greater change in D to be detected upon additional interactions 
with cytosolic factors. 
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